Stockreport

DESTINY-Endometrial02 Phase 3 Trial of ENHERTU® Initiated as Adjuvant Therapy in Patients with HER2 Expressing Endometrial Cancer

DAIICHI SANKYO S/ADR  (DSNKY) 
PDF TOKYO & BASKING RIDGE, N.J.--(BUSINESS WIRE)--The first patient has been dosed in the DESTINY-Endometrial02 phase 3 trial evaluating ENHERTU® (trastuzumab deruxtecan [Read more]